Keyphrases
Incremental Value
100%
Cancer Prediction
100%
ECG Markers
100%
Cancer Therapeutics-related Cardiac Dysfunction
100%
Echocardiogram
18%
Heart Failure
9%
Human Epidermal Growth Factor Receptor 2 (HER2)
9%
Quantitative Measurement
9%
Targeted Therapy
9%
Cancer Risk
9%
Cancer Treatment
9%
Cardiotoxicity
9%
Anthracyclines
9%
Multivariable
9%
Retrospective Cohort Study
9%
Female Patients
9%
Patients at Risk
9%
Risk Classification
9%
Left Ventricular Ejection Fraction
9%
Specific Factors
9%
New York Heart Association Class
9%
Risk Score
9%
Cox Proportional Hazards Model
9%
Subsequent Cancer
9%
Inclusion Criteria
9%
Clinical Risk Factors
9%
Likelihood Ratio Test
9%
ECG Parameters
9%
R Wave
9%
Net Reclassification Improvement
9%
Integrated Discrimination Improvement
9%
GE Healthcare
9%
QRS Axis
9%
Waveform Parameters
9%
ECG Waveform
9%
Wave Duration
9%
Human Epidermal Growth Factor Receptor 2-positive Breast Cancer
9%
ST-segment Deviation
9%
Clinical Cancer Therapy
9%
Risk Variables
9%
Variable Addition
9%
Medicine and Dentistry
Cancer Therapy
100%
Electrocardiogram
100%
Echocardiography
16%
Targeted Therapy
8%
Calcium Ion
8%
Retrospective Cohort Study
8%
New York Heart Association Class
8%
Heart Left Ventricle Ejection Fraction
8%
Gamma Urogastrone
8%
Epidermal Growth Factor Receptor 2
8%
Congestive Heart Failure
8%
Proportional Hazards Model
8%
ST Segment
8%
R Wave
8%
Anthracycline
8%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
8%
Primary Outcome
8%
Biochemistry, Genetics and Molecular Biology
Electrocardiogram
100%
Epidermal Growth Factor Receptor
28%
Quantitative Technique
14%
Cohort Study
14%
Electric Potential
14%
Heart Left Ventricle Ejection Fraction
14%
ST Segment
14%
R Wave
14%
Anthracycline
14%
Targeted Therapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Cohort Study
8%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
8%
Calcium Ion
8%
Congestive Heart Failure
8%
Gamma Urogastrone
8%
Epidermal Growth Factor Receptor 2
8%
Anthracycline
8%